Home
Markets
Charts & Ideas
Algo
News
Store
Brokers
Download
Stocks
Currencies
Cryptocurrencies
Metals
Indices
Commodities
ETFs
Type
/
to search: @user, $symbol
Search
Log in
Create an account
English
Русский
中文
Español
Português
日本語
Deutsch
한국어
Français
Italiano
Türkçe
News
Top Providers News
Top Providers News
Symbols
Market
Provider
Time
Symbols
News
Provider
2026.10.01
First Merchants Appoints Mike Stewart CEO, Effective 2027, Succeeding Mark Hardwick
Benzinga
2026.10.01
AI Threat? Accenture Posts Record Big-Ticket Client Bookings
Benzinga
2026.10.01
60 Degrees Pharmaceuticals To Present Data On Interim Analysis From Its Clinical Trial Of Tafenoquine On Oct. 6
Benzinga
2026.10.01
Candel Publishes Final Phase Of 2a Clinical Trial Results Of of Aglatimagene Besadenovec Plus Valacyclovir In Patients With Stage III/IV NSCLC Showing Inadequate Response To ICI.
Benzinga
2026.10.01
SpyGlass Pharma Acquires Advanced Vision Science For ~$13M In Cash
Benzinga
2026.10.01
Jim Cramer Recommends Buying This Energy Stock: It Is ‘Too Cheap’
Benzinga
2026.10.01
Aptera Motors Estimates It Needs ~$25M To Reach Start Of Production, Down From $40M-$45M, And ~$115M For Its Full Plan Through High-Volume Production, Down From $180M-$205M
Benzinga
2026.10.01
Antelope Enterprise Files Prospectus For Sale Of Up To $100M Shares Through Or To D. Boral Capital
Benzinga
2026.10.01
Next Technology Announces $35M R&D Initiative
Benzinga
2026.10.01
Meta, Millrose Properties, Cboe Global Markets And More On CNBC’s ‘Final Trades’
Benzinga
2026.10.01
How To Earn $500 A Month From Nike Stock Ahead Of Q1 Earnings
Benzinga
2026.10.01
Micron 'is a Beast': Ross Gerber Declares the Memory Chip Cycle Dead After Monster Earnings, Says 'I've Never Seen Anything Like This'
Benzinga
2026.10.01
Evommune Presents Additional Data From Phase 2a Proof-Of-Concept Trial Of EVO301 In Adults With Atopic Dermatitis At EADV 2026 Congress; Plan To Initiate Subcutaneous Phase 2b Dose-Ranging Trial In Mid-2027
Benzinga
2026.10.01
Kyndryl Opens Its First U.S. AI Innovation Lab In Dallas-Fort Worth
Benzinga
2026.10.01
Baird Maintains Neutral on Expeditors International, Raises Price Target to $200
Benzinga
2026.10.01
Taysha Gene Therapies Presents Multiple Encore Presentations For Its TSHA-102 Program At 55th Child Neurology Society Annual Meeting
Benzinga
2026.10.01
12 Industrials Stocks Moving In Thursday's Pre-Market Session
Benzinga
2026.10.01
12 Financials Stocks Moving In Thursday's Pre-Market Session
Benzinga
2026.10.01
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Benzinga
2026.10.01
12 Information Technology Stocks Moving In Thursday's Pre-Market Session
Benzinga
2026.10.01
McKesson Reiterates FY27 Adjusted EPS Outlook Range Of $44.20 To $45
Benzinga
2026.10.01
What's Going On With Synopsys Shares Thursday?
Benzinga
2026.10.01
Whitehawk Therapeutics Presents Two-Real World Analyses Supporting Mucin 16
Benzinga
2026.10.01
Stifel Maintains Hold on FactSet Research Systems, Raises Price Target to $292
Benzinga
2026.10.01
Corteva Completes Spin Off Of Its Advanced Seed And Genetics Business
Benzinga
2026.10.01
TEN Holdings Rolls Out Digital Experience Platform TEN
Benzinga
2026.10.01
Aktis Oncology Initiates Second Phase 1b Clinical Trial for AKY-2519
Benzinga
2026.10.01
Rosenblatt Maintains Buy on Synopsys, Raises Price Target to $620
Benzinga
2026.10.01
CNH Industrial Reports Q2 2026 Results: Full Earnings Call Transcript
Benzinga
2026.10.01
Vylor Completes Its Separation From Corteva, To Trade On Nasdaq Under VYLR Symbol
Benzinga
1
...
1109
1110
1111
1112
1113
1114
1115
1116
>